In fact, PI3K and AKT inhibitors, in several preclinical studies, were demonstrated to be able to reduce SOX2-driven growth, viability, migration, tumorigenicity, and drug resistance of cancer cells (24). This evidence concerns the gene SOX2 and cancer.